Skip to main content

Month: April 2026

NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit

SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present data on its lead investigational program, troculeucel, at the 8th Annual Neuroimmunology Drug Development Summit being held April 14-16, 2026, in Boston, Massachusetts. NKGen’s Chairman and Chief Executive Officer, Dr. Paul Y. Song, M.D., will highlight the therapeutic rationale supporting troculeucel’s use in neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia (“FTD”). The presentation will include an overview of the Company’s expanding mechanistic dataset, including evidence...

Continue reading

American Rare Earths Defines Wyoming-Led Pilot Plant Pathway to Accelerate Pre-Production Rare Earth Oxide

DENVER, April 09, 2026 (GLOBE NEWSWIRE) — American Rare Earths (ASX: ARR | OTCQX: ARRNF | ADR: AMRRY) (“ARR” or the “Company”) is pleased to announce the next stage in its accelerated pilot plant program for the American Rare Earths Halleck Creek Project in Wyoming, with initial processing to be undertaken in Wyoming through DISA Technologies (“DISA”) and Western Research Institute followed by final stage hydrometallurgical processing and oxide separation at the Saskatchewan Research Council (“SRC”) in Saskatoon, Saskatchewan, Canada. The Company has executed agreements with Western Research Institute, DISA and SRC to provide mineral processing activities at their respective locations. Building on the pilot plant pathway announced on April 1, 20261, the Company has now further defined an execution plan that keeps the front end of...

Continue reading

Byrna Technologies Reports Fiscal First Quarter 2026 Results

Outlines Strategic Priorities Focused on Retail Channel Execution, Broader Customer Reach, Improved Conversion, and Operating Leverage Under New CEO Conn Davis ANDOVER, Mass., April 09, 2026 (GLOBE NEWSWIRE) — Byrna Technologies Inc. (“Byrna” or the “Company”) (Nasdaq: BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, today reported select financial results for its fiscal first quarter (“Q1 2026”) ended February 28, 2026. Fiscal First Quarter 2026 and Recent Operational HighlightsAppointed Conn Davis as Chief Executive Officer, succeeding retiring CEO Bryan Ganz. Davis brings deep experience scaling consumer brands across product innovation, distribution, e-commerce, and M&A. Began partnership with Academy Sports + Outdoors,...

Continue reading

Northern Technologies International Corporation Reports Financial Results for Second Quarter Fiscal 2026

MINNEAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) — Northern Technologies International Corporation (NASDAQ: NTIC), a leading developer of corrosion inhibiting products and services, as well as bio-based and biodegradable polymer resin compounds, today reported its financial results for the second quarter of fiscal 2026. Second quarter fiscal 2026 financial and operating highlights include (with growth rates on a fiscal quarter year-over-year basis):Consolidated net sales increased 15.3% to a record second quarter of $21,997,000 ZERUST® industrial net sales increased 11.2% to $13,967,000 ZERUST® oil and gas net sales increased 72.1% to a second quarter record of $2,666,000 Natur-Tec® product net sales increased 8.1% to $5,363,000 NTIC China net sales increased 18.5% to $4,425,000 Gross profit, as a percentage of net sales, increased...

Continue reading

NowVertical Group Reports Fourth Quarter 2025 Financial Results

Company Hosting Investor Webinar on Thursday, April 9, 2026, at 11:00 AM ET TORONTO, April 09, 2026 (GLOBE NEWSWIRE) — NowVertical Group Inc. (TSX-V: NOW) (“NOW” or the “Company”), a leader in AI-driven data solutions, announces financial results for its fourth fiscal quarter and year ended December 31, 2025. Unless otherwise specified, all dollar amounts are expressed in U.S. dollars. Management will host an investor webinar at 11:00 AM ET (8:00 AM PT) on Thursday, April 9th, to discuss the Company’s financial and business results. “Our FY 2025 results reflect a combination of external and transitional factors, including foreign exchange impacts in Argentina and lower reseller revenue in certain markets, which affected reported revenue for both the quarter and the year,” said Sandeep Mendiratta, Chief Executive Officer of the Company. “At...

Continue reading

Electra Awards $7.8 Million in Construction Contracts for Refinery Infrastructure

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”), a North American critical minerals refining company, today announced the award of approximately C$7.8 million in construction contracts related to key infrastructure within its cobalt sulfate refinery in Ontario. The contracts establish defined construction scopes across key process areas, bringing additional portions of the refinery into active execution. Electra has awarded a contract valued at approximately C$6.8 million for structural, mechanical, and piping work associated with the refinery’s crystallizer circuit. The work is being executed by Pro Pipe Construction Ltd., a Northern Ontario-based subsidiary of Dalcon Construction, and includes fabrication and installation of piping systems...

Continue reading

AGF Launches Capitol Signals, a Subscription-Based Newsletter

Henrietta Treyz Joins as Contributor, Bringing Timely U.S. Policy and Economic Insight for Subscribers TORONTO, April 09, 2026 (GLOBE NEWSWIRE) — AGF Management Limited (AGF) today announced that Henrietta Treyz, Co-Founder and Director of Economic Policy at Veda Partners, will become a regular contributor as the firm launches Capitol Signals, a subscription-based newsletter. She will provide subscribers with weekly and ad hoc insights into how U.S. policy and political developments may impact global markets. Issues such as tariffs, fiscal stimulus, tax policy, the debt ceiling, and other key economic priorities in Washington, D.C will be covered. “Henrietta brings deep expertise in economic policy and a strong track record of helping investors understand the implications of political and legislative developments,” said Meaghan...

Continue reading

FTI Consulting to Release First Quarter 2026 Results and Host Conference Call

WASHINGTON, April 09, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that it will release financial results for the first quarter ended March 31, 2026 before the New York market opens on Thursday, April 30, 2026. A conference call will be held to discuss these financial results on Thursday, April 30, 2026, at 9:00 a.m. Eastern Time and will be hosted by senior management. The conference call will be simulcast live on the Internet and can be accessed by logging onto the Company’s investor relations website. A replay of the webcast will be available on the Company’s investor relations website for 90 days. About FTI ConsultingFTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories...

Continue reading

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will present updated data from its ongoing FIT-001 clinical trial (NCT 06026410) evaluating darlifarnib (KO-2806) in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma at the International Kidney Cancer Symposium (IKCS) Europe 2026 in Paris, France. The data to be presented build on earlier findings from the FIT-001 study reported at the 2025 European Society for Medical Oncology...

Continue reading

Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

Seasoned biotech executive brings deep experience across clinical development, regulatory strategy, and corporate operations, strengthening execution capabilities as Plus advances REYOBIQ™ and CNS-focused pipeline HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the appointment of Eric J. Daniels, M.D., MBA, as Chief Development Officer, effective April 20, 2026. Dr. Daniels is a seasoned biotechnology executive with more than two decades of experience spanning clinical development, regulatory strategy, corporate operations, and business development. He most recently served as Chief Development Officer at Kiora...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.